1. Home
  2. PRME vs SLI Comparison

PRME vs SLI Comparison

Compare PRME & SLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

HOLD

Current Price

$3.02

Market Cap

536.4M

Sector

Health Care

ML Signal

HOLD

Logo Standard Lithium Ltd.

SLI

Standard Lithium Ltd.

HOLD

Current Price

$2.38

Market Cap

524.3M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRME
SLI
Founded
2019
1998
Country
United States
Canada
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Major Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
536.4M
524.3M
IPO Year
2022
2011

Fundamental Metrics

Financial Performance
Metric
PRME
SLI
Price
$3.02
$2.38
Analyst Decision
Buy
Strong Buy
Analyst Count
6
3
Target Price
$7.56
$5.25
AVG Volume (30 Days)
3.1M
1.6M
Earning Date
05-08-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
18.18
N/A
EPS
N/A
N/A
Revenue
$4,632,000.00
N/A
Revenue This Year
$7.06
N/A
Revenue Next Year
$47.01
N/A
P/E Ratio
N/A
N/A
Revenue Growth
55.28
N/A
52 Week Low
$2.67
$1.91
52 Week High
$6.94
$6.40

Technical Indicators

Market Signals
Indicator
PRME
SLI
Relative Strength Index (RSI) 42.71 44.52
Support Level $2.74 $2.08
Resistance Level $3.60 $4.38
Average True Range (ATR) 0.18 0.12
MACD -0.02 0.06
Stochastic Oscillator 46.00 85.71

Price Performance

Historical Comparison
PRME
SLI

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

About SLI Standard Lithium Ltd.

Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company's flagship projects are located in the Smackover Formation, a world-class lithium brine asset, focused in Arkansas and Texas. It is also Standard Lithium is advancing the South West Arkansas project, a greenfield project located in southern Arkansas, and strengthening lithium brine prospects in East Texas. Its other project comprises the Lanxess Property Project; and California Properties. The technologies used for the projects are : Direct Lithium Extraction; Demonstration Plant; SiFT; Lithium Sulfide; and Aqualung.

Share on Social Networks: